BeOne Medicines

ONCApproved

BeOne Medicines is building the world's leading oncology company through scientific excellence and global reach, serving patients across 45+ countries with 12,000+ employees. The company has successfully transitioned from development to commercialization with approved therapies generating significant revenue. With substantial U.S. investment including $750M in R&D and a 400,000 square foot manufacturing facility, BeOne is positioned as a major player in global cancer treatment.

Market Cap

$28.1B

Employees

11,000-12,000

Focus

AntibodiesBiologicsSmall Molecules

ONC · Stock Price

USD 275.28+82.66 (+42.91%)

Historical price data

AI Company Overview

Technology Platform

BeOne develops targeted oncology therapies with focus on BTK inhibition, BCL2 inhibition, and protein degradation through their CDAC platform, supported by advanced biomarker research capabilities.

Pipeline Snapshot

84 drugs in pipeline, 18 in Phase 3

Drug	Indication	Stage
Zanubrutinib	Waldenström's Macroglobulinemia	Approved
Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + Carboplatin	Urothelial Carcinoma	Phase 3
Sonrotoclax + Zanubrutinib + Placebo	Mantle Cell Lymphoma	Phase 3
BGB-16673 + Bendamustine + Rituximab + Methylprednisolone	Chronic Lymphocytic Leukemia	Phase 3
Tislelizumab + Cisplatin injection + Paclitaxel injection + Pemetrexed Disodium ...	Non Small Cell Lung Cancer	Phase 3

Funding History

Total raised: $175M

IPOUndisclosedUndisclosedOct 13, 2023

Series B$125MRA Capital ManagementJun 15, 2021

Series A$50MOrbiMedJun 15, 2020

FDA Approved Drugs

BRUKINSANDAJun 10, 2025

TEVIMBRABLAMar 13, 2024

BRUKINSANDANov 14, 2019

Opportunities

BeOne is positioned for significant growth through pipeline advancement across multiple cancer types, global expansion into underserved markets, and leveraging their manufacturing capabilities to support worldwide distribution.

The company's established commercial products provide a strong foundation for reinvestment in R&D and strategic acquisitions.

Risk Factors

Key risks include intense competition in the oncology market with rapid innovation cycles, regulatory challenges across multiple global jurisdictions, and potential clinical trial failures that could impact pipeline value.

Market access and pricing pressures in key markets also pose ongoing challenges to revenue growth.

Competitive Landscape

BeOne competes against major pharmaceutical companies like Roche, Bristol Myers Squibb, and Merck in oncology, while also facing competition from emerging biotech companies. The company differentiates through its global manufacturing capabilities, comprehensive patient support programs, and focus on reaching underserved patient populations worldwide.

Publications

Pipeline

FDA Approvals